FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072480954> ?p ?o ?g. }

• W2072480954 endingPage "651" @default.
• W2072480954 startingPage "651" @default.
• W2072480954 abstract "Diabetes is the most important risk factors for chronic kidney disease (CKD). The risk of CKD attributable to diabetes continues to rise worldwide. Diabetic patients with CKD need complicated treatment for their metabolic disorders as well as for related comorbidities. They have to treat, often intensively, hypertension, dyslipidaemia, bone disease, anaemia, and frequently established cardiovascular disease. The treatment of hypoglycaemia in diabetic persons with CKD must tie their individual goals of glycaemia (usually less tight glycaemic control) and knowledge on the pharmacokinetics and pharmacodynamics of drugs available to a person with kidney disease. The problem is complicated from the fact that in many efficacy studies patients with CKD are excluded so data of safety and efficacy for these patients are missing. This results in fear of use by lack of evidence. Metformin is globally accepted as the first choice in practically all therapeutic algorithms for diabetic subjects. The advantages of metformin are low risk of hypoglycaemia, modest weight loss, effectiveness and low cost. Data of UKPDS indicate that treatment based on metformin results in less total as well cardiovascular mortality. Metformin remains the drug of choice for patients with diabetes and CKD provided that their estimate Glomerular Filtration Rate (eGFR) remains above 30 mL/min per square meter. For diabetic patients with eGFR between 30-60 mL/min per square meter more frequent monitoring of renal function and dose reduction of metformin is needed. The use of sulfonylureas, glinides and insulin carry a higher risk of hypoglycemia in these patients and must be very careful. Lower doses and slower titration of the dose is needed. Is better to avoid sulfonylureas with active hepatic metabolites, which are renally excreted. Very useful drugs for this group of patients emerge dipeptidyl peptidase 4 inhibitors. These drugs do not cause hypoglycemia and most of them (linagliptin is an exception) require dose reduction in various stages of renal disease." @default.
• W2072480954 created "2016-06-24" @default.
• W2072480954 creator A5080008170 @default.
• W2072480954 date "2014-01-01" @default.
• W2072480954 modified "2023-10-14" @default.
• W2072480954 title "Diabetes treatment in patients with renal disease: Is the landscape clear enough?" @default.
• W2072480954 cites W1510325795 @default.
• W2072480954 cites W1596584892 @default.
• W2072480954 cites W1596678070 @default.
• W2072480954 cites W1691075749 @default.
• W2072480954 cites W1970343079 @default.
• W2072480954 cites W1986044732 @default.
• W2072480954 cites W1993270448 @default.
• W2072480954 cites W1997042641 @default.
• W2072480954 cites W2001097346 @default.
• W2072480954 cites W2010396854 @default.
• W2072480954 cites W2029378794 @default.
• W2072480954 cites W2032167210 @default.
• W2072480954 cites W2044398229 @default.
• W2072480954 cites W2051088920 @default.
• W2072480954 cites W2058933537 @default.
• W2072480954 cites W2060124483 @default.
• W2072480954 cites W2061351888 @default.
• W2072480954 cites W2075182875 @default.
• W2072480954 cites W2079841945 @default.
• W2072480954 cites W2103075451 @default.
• W2072480954 cites W2110344696 @default.
• W2072480954 cites W2112475150 @default.
• W2072480954 cites W2128116779 @default.
• W2072480954 cites W2133533488 @default.
• W2072480954 cites W2138045215 @default.
• W2072480954 cites W2140536043 @default.
• W2072480954 cites W2141065273 @default.
• W2072480954 cites W2142357564 @default.
• W2072480954 cites W2147779427 @default.
• W2072480954 cites W2154277743 @default.
• W2072480954 cites W2154719797 @default.
• W2072480954 cites W2302636078 @default.
• W2072480954 cites W2904387867 @default.
• W2072480954 doi "https://doi.org/10.4239/wjd.v5.i5.651" @default.
• W2072480954 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4138588" @default.
• W2072480954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25317242" @default.
• W2072480954 hasPublicationYear "2014" @default.
• W2072480954 type Work @default.
• W2072480954 sameAs 2072480954 @default.
• W2072480954 citedByCount "50" @default.
• W2072480954 countsByYear W20724809542014 @default.
• W2072480954 countsByYear W20724809542015 @default.
• W2072480954 countsByYear W20724809542016 @default.
• W2072480954 countsByYear W20724809542017 @default.
• W2072480954 countsByYear W20724809542018 @default.
• W2072480954 countsByYear W20724809542019 @default.
• W2072480954 countsByYear W20724809542020 @default.
• W2072480954 countsByYear W20724809542021 @default.
• W2072480954 countsByYear W20724809542022 @default.
• W2072480954 countsByYear W20724809542023 @default.
• W2072480954 crossrefType "journal-article" @default.
• W2072480954 hasAuthorship W2072480954A5080008170 @default.
• W2072480954 hasBestOaLocation W20724809541 @default.
• W2072480954 hasConcept C126322002 @default.
• W2072480954 hasConcept C134018914 @default.
• W2072480954 hasConcept C159641895 @default.
• W2072480954 hasConcept C177713679 @default.
• W2072480954 hasConcept C2777180221 @default.
• W2072480954 hasConcept C2778653478 @default.
• W2072480954 hasConcept C2779134260 @default.
• W2072480954 hasConcept C2780323712 @default.
• W2072480954 hasConcept C2780668416 @default.
• W2072480954 hasConcept C555293320 @default.
• W2072480954 hasConcept C71924100 @default.
• W2072480954 hasConceptScore W2072480954C126322002 @default.
• W2072480954 hasConceptScore W2072480954C134018914 @default.
• W2072480954 hasConceptScore W2072480954C159641895 @default.
• W2072480954 hasConceptScore W2072480954C177713679 @default.
• W2072480954 hasConceptScore W2072480954C2777180221 @default.
• W2072480954 hasConceptScore W2072480954C2778653478 @default.
• W2072480954 hasConceptScore W2072480954C2779134260 @default.
• W2072480954 hasConceptScore W2072480954C2780323712 @default.
• W2072480954 hasConceptScore W2072480954C2780668416 @default.
• W2072480954 hasConceptScore W2072480954C555293320 @default.
• W2072480954 hasConceptScore W2072480954C71924100 @default.
• W2072480954 hasIssue "5" @default.
• W2072480954 hasLocation W20724809541 @default.
• W2072480954 hasLocation W20724809542 @default.
• W2072480954 hasLocation W20724809543 @default.
• W2072480954 hasLocation W20724809544 @default.
• W2072480954 hasOpenAccess W2072480954 @default.
• W2072480954 hasPrimaryLocation W20724809541 @default.
• W2072480954 hasRelatedWork W2017470589 @default.
• W2072480954 hasRelatedWork W2080042754 @default.
• W2072480954 hasRelatedWork W2394348404 @default.
• W2072480954 hasRelatedWork W2550868627 @default.
• W2072480954 hasRelatedWork W2790532628 @default.
• W2072480954 hasRelatedWork W3130171081 @default.
• W2072480954 hasRelatedWork W4255799541 @default.
• W2072480954 hasRelatedWork W4283768941 @default.
• W2072480954 hasRelatedWork W4320929188 @default.
• W2072480954 hasRelatedWork W1920632900 @default.

• next